Author:
Singh Avneesh K.,Goerlich Corbin E.,Shah Aakash M.,Zhang Tianshu,Tatarov Ivan,Ayares David,Horvath Keith A.,Mohiuddin Muhammad M.
Abstract
Survival of pig cardiac xenografts in a non-human primate (NHP) model has improved significantly over the last 4 years with the introduction of costimulation blockade based immunosuppression (IS) and genetically engineered (GE) pig donors. The longest survival of a cardiac xenograft in the heterotopic (HHTx) position was almost 3 years and only rejected when IS was stopped. Recent reports of cardiac xenograft survival in a life-sustaining orthotopic (OHTx) position for 6 months is a significant step forward. Despite these achievements, there are still several barriers to the clinical success of xenotransplantation (XTx). This includes the possible transmission of porcine pathogens with pig donors and continued xenograft growth after XTx. Both these concerns, and issues with additional incompatibilities, have been addressed recently with the genetic modification of pigs. This review discusses the spectrum of issues related to cardiac xenotransplantation, recent progress in preclinical models, and its feasibility for clinical translation.
Reference114 articles.
1. Endothelial Expression of Human Decay Accelerating Factor in Transgenic Pig Tissue: a Potential Approach for Human Complement Inactivation in Discordant Xenografts;Rosengard;Transpl Proc,1995
2. Targeted Disruption of the α1,3-galactosyltransferase Gene in Cloned Pigs;Dai;Nat Biotechnol,2002
3. Production of α-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning;Lai;Science,2002
4. Production of α1,3-Galactosyltransferase-Deficient Pigs;Phelps;Science,2003
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献